{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,5]],"date-time":"2026-05-05T04:25:22Z","timestamp":1777955122522,"version":"3.51.4"},"reference-count":85,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Paediatric Respiratory Reviews"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.prrv.2025.06.003","type":"journal-article","created":{"date-parts":[[2025,6,18]],"date-time":"2025-06-18T15:46:49Z","timestamp":1750261609000},"page":"45-61","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["Choosing biologic therapy in children with severe asthma"],"prefix":"10.1016","volume":"58","author":[{"given":"Latika","family":"Gupta","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michele","family":"Arigliani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"James","family":"Cook","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Atul","family":"Gupta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"10379","key":"10.1016\/j.prrv.2025.06.003_b0005","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1016\/S0140-6736(22)02125-0","article-title":"Asthma","volume":"401","author":"Porsbjerg","year":"2023","journal-title":"Lancet"},{"key":"10.1016\/j.prrv.2025.06.003_b0010","unstructured":"England, N. Asthma in children. 2024 [cited 2024; Available from: https:\/\/www.england.nhs.uk\/childhood-asthma\/."},{"issue":"3","key":"10.1016\/j.prrv.2025.06.003_b0015","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.00765-2017","article-title":"\u201cI have lost in every facet of my life\u201d: the hidden burden of severe asthma","volume":"50","author":"Foster","year":"2017","journal-title":"Eur Respir J"},{"key":"10.1016\/j.prrv.2025.06.003_b0020","doi-asserted-by":"crossref","first-page":"186","DOI":"10.3389\/fped.2018.00186","article-title":"The burden of pediatric asthma","volume":"6","author":"Ferrante","year":"2018","journal-title":"Front Pediatr"},{"key":"10.1016\/j.prrv.2025.06.003_b0025","unstructured":"GINA. Global strategy for asthma management and prevention 2024; Available from: https:\/\/ginasthma.org\/2024-report\/."},{"key":"10.1016\/j.prrv.2025.06.003_b0030","unstructured":"BTS\/SIGN. Asthma Guidelines 2024. 2024 2024]; Available from: https:\/\/www.brit-thoracic.org.uk\/news\/2024\/new-joint-guideline-recommends-healthcare-professionals-prescribe-combination-treatments-rather-than-reliever-medications-alone-for-people-with-newly-diagnosed-asthma\/."},{"key":"10.1016\/j.prrv.2025.06.003_b0035","doi-asserted-by":"crossref","first-page":"123","DOI":"10.2147\/JAA.S129159","article-title":"Managing the pediatric patient with refractory asthma: a multidisciplinary approach","volume":"10","author":"Cook","year":"2017","journal-title":"J Asthma Allergy"},{"issue":"8","key":"10.1016\/j.prrv.2025.06.003_b0040","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1111\/resp.14520","article-title":"Biologics for severe asthma\u2014which, when and why?","volume":"28","author":"Shah","year":"2023","journal-title":"Respirology"},{"issue":"4","key":"10.1016\/j.prrv.2025.06.003_b0045","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1016\/j.anai.2018.07.029","article-title":"Use of biomarkers to identify phenotypes and endotypes of severeasthma","volume":"121","author":"Carr","year":"2018","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"9","key":"10.1016\/j.prrv.2025.06.003_b0050","doi-asserted-by":"crossref","first-page":"2310","DOI":"10.1016\/j.jaip.2024.06.010","article-title":"Type 2 inflammation and asthma in children: a narrative review","volume":"12","author":"Papadopoulos","year":"2024","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"5","key":"10.1016\/j.prrv.2025.06.003_b0055","doi-asserted-by":"crossref","first-page":"1969","DOI":"10.1016\/j.jaip.2020.12.027","article-title":"Factors associated with asthma severity in children: data from the French COBRAPed cohort","volume":"9","author":"Lezmi","year":"2021","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.prrv.2025.06.003_b0060","doi-asserted-by":"crossref","first-page":"122","DOI":"10.3389\/fped.2017.00122","article-title":"How much asthma is atopic in children?","volume":"5","author":"Comberiati","year":"2017","journal-title":"Front Pediatr"},{"issue":"10","key":"10.1016\/j.prrv.2025.06.003_b0065","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.1016\/S2213-2600(20)30399-4","article-title":"Advances in understanding and reducing the burden of severe asthma in children","volume":"8","author":"Pijnenburg","year":"2020","journal-title":"Lancet Respir Med"},{"issue":"5","key":"10.1016\/j.prrv.2025.06.003_b0070","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.1378\/chest.09-3058","article-title":"Expression of the T helper 17-associated cytokines IL-17A and IL-17F in asthma and COPD","volume":"138","author":"Doe","year":"2010","journal-title":"Chest"},{"issue":"10","key":"10.1016\/j.prrv.2025.06.003_b0075","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1136\/thorax.57.10.875","article-title":"Analysis of induced sputum in adults with asthma: identification of subgroup with isolated sputum neutrophilia and poor response to inhaled corticosteroids","volume":"57","author":"Green","year":"2002","journal-title":"Thorax"},{"issue":"4","key":"10.1016\/j.prrv.2025.06.003_b0080","doi-asserted-by":"crossref","DOI":"10.3390\/biomedicines11041226","article-title":"T2-low asthma: a discussed but still orphan disease","volume":"11","author":"Peri","year":"2023","journal-title":"Biomedicines"},{"key":"10.1016\/j.prrv.2025.06.003_b0085","unstructured":"NICE. Omalizumab for severe persistent allergic asthma. 2013; Available from: https:\/\/www.nice.org.uk\/guidance\/ta278\/resources\/omalizumab-for-severe-persistent-allergic-asthma-pdf-425322541#:\u223c:text=You%20(or%20your%20child)%20should,you%20(or%20your%20child)%3A&text=have%20been%20diagnosed%20with%20a,courses%20in%20the%20last%20year)."},{"key":"10.1016\/j.prrv.2025.06.003_b0090","unstructured":"(FDA), F.a.D.a. Omalizumab in children with asthma. 2016 [cited 2024; Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2021\/103976s5238lbl.pdf."},{"key":"10.1016\/j.prrv.2025.06.003_b0095","unstructured":"Novartis X. Xolair for allergic asthma. [cited 2024; Available from: https:\/\/www.xolair.com\/allergic-asthma.html."},{"issue":"8 Pt 2","key":"10.1016\/j.prrv.2025.06.003_b0100","doi-asserted-by":"crossref","first-page":"S12","DOI":"10.1164\/ajrccm.164.supplement_1.2103026","article-title":"Anti-immunoglobulin E (omalizumab) therapy in allergic asthma","volume":"164","author":"Busse","year":"2001","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.prrv.2025.06.003_b0105","article-title":"Omalizumab for asthma in adults and children","volume":"1","author":"Normansell","year":"2014","journal-title":"Cochrane Database Syst Rev"},{"issue":"6","key":"10.1016\/j.prrv.2025.06.003_b0110","doi-asserted-by":"crossref","first-page":"1210","DOI":"10.1016\/j.jaci.2009.09.021","article-title":"Omalizumab for the treatment of exacerbations in children with inadequately controlled allergic (IgE-mediated) asthma","volume":"124","author":"Lanier","year":"2009","journal-title":"J Allergy Clin Immunol"},{"issue":"2","key":"10.1016\/j.prrv.2025.06.003_b0115","doi-asserted-by":"crossref","first-page":"E36","DOI":"10.1542\/peds.108.2.e36","article-title":"Treatment of childhood asthma with anti-immunoglobulin E antibody (omalizumab)","volume":"108","author":"Milgrom","year":"2001","journal-title":"Pediatrics"},{"issue":"1","key":"10.1016\/j.prrv.2025.06.003_b0120","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/j.jaip.2018.04.043","article-title":"Omalizumab effectiveness by biomarker status in patients with asthma: evidence from PROSPERO, a prospective real-world study","volume":"7","author":"Casale","year":"2019","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"5","key":"10.1016\/j.prrv.2025.06.003_b0125","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.1183\/09031936.00149812","article-title":"Add-on omalizumab in children with severe allergic asthma: a 1-year real life survey","volume":"42","author":"Deschildre","year":"2013","journal-title":"Eur Respir J"},{"issue":"7","key":"10.1016\/j.prrv.2025.06.003_b0130","doi-asserted-by":"crossref","first-page":"2702","DOI":"10.1016\/j.jaip.2021.01.011","article-title":"Real-world effectiveness of omalizumab in severe allergic asthma: a meta-analysis of observational studies","volume":"9","author":"Bousquet","year":"2021","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"8","key":"10.1016\/j.prrv.2025.06.003_b0135","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1164\/rccm.201208-1414OC","article-title":"Exploring the effects of omalizumab in allergic asthma: an analysis of biomarkers in the EXTRA study","volume":"187","author":"Hanania","year":"2013","journal-title":"Am J Respir Crit Care Med"},{"issue":"2","key":"10.1016\/j.prrv.2025.06.003_b0140","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1177\/08971900211038251","article-title":"Effectiveness and safety studies of omalizumab in children and adolescents with moderate-to-severe asthma","volume":"36","author":"Cheng","year":"2023","journal-title":"J Pharm Pract"},{"issue":"4","key":"10.1016\/j.prrv.2025.06.003_b0145","doi-asserted-by":"crossref","first-page":"1378","DOI":"10.1378\/chest.125.4.1378","article-title":"Predicting response to omalizumab, an anti-IgE antibody, in patients with allergic asthma","volume":"125","author":"Bousquet","year":"2004","journal-title":"Chest"},{"issue":"12","key":"10.1016\/j.prrv.2025.06.003_b0150","doi-asserted-by":"crossref","first-page":"1780","DOI":"10.1111\/j.1398-9995.2009.02119.x","article-title":"Relationship between pretreatment specific IgE and the response to omalizumab therapy","volume":"64","author":"Wahn","year":"2009","journal-title":"Allergy"},{"issue":"10","key":"10.1016\/j.prrv.2025.06.003_b0155","doi-asserted-by":"crossref","first-page":"1472","DOI":"10.1111\/all.12922","article-title":"Utility of serum periostin and free IgE levels in evaluating responsiveness to omalizumab in patients with severe asthma","volume":"71","author":"Tajiri","year":"2016","journal-title":"Allergy"},{"issue":"3","key":"10.1016\/j.prrv.2025.06.003_b0160","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1016\/j.jaci.2023.01.002","article-title":"Biologics in the treatment of asthma in children and adolescents","volume":"151","author":"Bacharier","year":"2023","journal-title":"J Allergy Clin Immunol"},{"issue":"7","key":"10.1016\/j.prrv.2025.06.003_b0165","doi-asserted-by":"crossref","DOI":"10.3390\/biomedicines9070760","article-title":"Biologic therapy and severe asthma in children","volume":"9","author":"Russo","year":"2021","journal-title":"Biomedicines"},{"issue":"1","key":"10.1016\/j.prrv.2025.06.003_b0170","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1185\/03007995.2010.539502","article-title":"Safety and tolerability of omalizumab in children with allergic (IgE-mediated) asthma","volume":"27","author":"Milgrom","year":"2011","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.prrv.2025.06.003_b0175","unstructured":"Excellence, N.I.o.H.a.c. Mepolizumab for treating severe eosinophilic asthma (NICE technology appraisal guidance Ta671). 2021; Available from: https:\/\/www.nice.org.uk\/guidance\/ta671."},{"key":"10.1016\/j.prrv.2025.06.003_b0180","unstructured":"(FDA), F.a.D.A. Mepolizumab FDA. 2023 [cited 2024; Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2023\/125526Orig1s021,761122Orig1s011Corrected_lbl.pdf."},{"key":"10.1016\/j.prrv.2025.06.003_b0185","unstructured":"GSK N. Mepolizumab for asthma pre filled syringes. [cited 2024; Available from: https:\/\/us.gsk.com\/en-us\/media\/press-releases\/fda-approves-nucala-mepolizumab-40-mg-prefilled-syringe-for-children-with-severe-eosinophilic-asthma\/."},{"issue":"2","key":"10.1016\/j.prrv.2025.06.003_b0190","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1053\/j.seminhematol.2012.01.005","article-title":"Eosinophils and disease pathogenesis","volume":"49","author":"Akuthota","year":"2012","journal-title":"Semin Hematol"},{"issue":"3","key":"10.1016\/j.prrv.2025.06.003_b0195","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1111\/all.15056","article-title":"From DREAM to REALITI-A and beyond: Mepolizumab for the treatment of eosinophil-driven diseases","volume":"77","author":"Pavord","year":"2022","journal-title":"Allergy"},{"issue":"13","key":"10.1016\/j.prrv.2025.06.003_b0200","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1056\/NEJMoa1403290","article-title":"Mepolizumab treatment in patients with severe eosinophilic asthma","volume":"371","author":"Ortega","year":"2014","journal-title":"N Engl J Med"},{"issue":"13","key":"10.1016\/j.prrv.2025.06.003_b0205","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1056\/NEJMoa1403291","article-title":"Oral glucocorticoid-sparing effect of mepolizumab in eosinophilic asthma","volume":"371","author":"Bel","year":"2014","journal-title":"N Engl J Med"},{"issue":"9","key":"10.1016\/j.prrv.2025.06.003_b0210","doi-asserted-by":"crossref","first-page":"2058","DOI":"10.1016\/j.clinthera.2016.07.010","article-title":"Long-term efficacy and safety of mepolizumab in patients with severe eosinophilic asthma: a multi-center, open-label phase IIIb study","volume":"38","author":"Lugogo","year":"2016","journal-title":"Clin Ther"},{"issue":"9842","key":"10.1016\/j.prrv.2025.06.003_b0215","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1016\/S0140-6736(12)60988-X","article-title":"Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial","volume":"380","author":"Pavord","year":"2012","journal-title":"Lancet"},{"issue":"5","key":"10.1016\/j.prrv.2025.06.003_b0220","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1016\/S2213-2600(17)30125-X","article-title":"Efficacy of mepolizumab add-on therapy on health-related quality of life and markers of asthma control in severe eosinophilic asthma (MUSCA): a randomised, double-blind, placebo-controlled, parallel-group, multicentre, phase 3b trial","volume":"5","author":"Chupp","year":"2017","journal-title":"Lancet Respir Med"},{"issue":"10351","key":"10.1016\/j.prrv.2025.06.003_b0225","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1016\/S0140-6736(22)01198-9","article-title":"Mepolizumab for urban children with exacerbation-prone eosinophilic asthma in the USA (MUPPITS-2): a randomised, double-blind, placebo-controlled, parallel-group trial","volume":"400","author":"Jackson","year":"2022","journal-title":"Lancet"},{"issue":"12","key":"10.1016\/j.prrv.2025.06.003_b0230","doi-asserted-by":"crossref","first-page":"1957","DOI":"10.1002\/ppul.24508","article-title":"Subcutaneous mepolizumab in children aged 6 to 11 years with severe eosinophilic asthma","volume":"54","author":"Gupta","year":"2019","journal-title":"Pediatr Pulmonol"},{"issue":"5","key":"10.1016\/j.prrv.2025.06.003_b0235","doi-asserted-by":"crossref","first-page":"1336","DOI":"10.1016\/j.jaci.2019.08.005","article-title":"Long-term safety and pharmacodynamics of mepolizumab in children with severe asthma with an eosinophilic phenotype","volume":"144","author":"Gupta","year":"2019","journal-title":"J Allergy Clin Immunol"},{"issue":"5","key":"10.1016\/j.prrv.2025.06.003_b0240","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.01874-2019","article-title":"Blood eosinophil count in the general population: typical values and potential confounders","volume":"55","author":"Hartl","year":"2020","journal-title":"Eur Respir J"},{"key":"10.1016\/j.prrv.2025.06.003_b0245","unstructured":"NICE, B.f.t.s.e.a. Benralizumab for treating severe eosinophilic asthma. 2019 [cited 2024; Available from: https:\/\/www.nice.org.uk\/guidance\/ta565."},{"key":"10.1016\/j.prrv.2025.06.003_b0250","unstructured":"FDA. Benralizumab approval in children. 2024 [cited 2024 11\/10\/2024]; Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2024\/761070s021lbl.pdf."},{"issue":"1","key":"10.1016\/j.prrv.2025.06.003_b0255","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1517\/14712598.2012.642359","article-title":"Benralizumab\u2013a humanized mAb to IL-5R\u03b1 with enhanced antibody-dependent cell-mediated cytotoxicity\u2013a novel approach for the treatment of asthma","volume":"12","author":"Ghazi","year":"2012","journal-title":"Expert Opin Biol Ther"},{"issue":"3","key":"10.1016\/j.prrv.2025.06.003_b0260","doi-asserted-by":"crossref","DOI":"10.1111\/pai.14092","article-title":"Benralizumab in children with severe eosinophilic asthma: pharmacokinetics and long-term safety (TATE study)","volume":"35","author":"Wedner","year":"2024","journal-title":"Pediatr Allergy Immunol"},{"issue":"10056","key":"10.1016\/j.prrv.2025.06.003_b0265","doi-asserted-by":"crossref","first-page":"2115","DOI":"10.1016\/S0140-6736(16)31324-1","article-title":"Efficacy and safety of benralizumab for patients with severe asthma uncontrolled with high-dosage inhaled corticosteroids and long-acting \u03b22-agonists (SIROCCO): a randomised, multicentre, placebo-controlled phase 3 trial","volume":"388","author":"Bleecker","year":"2016","journal-title":"Lancet"},{"issue":"10056","key":"10.1016\/j.prrv.2025.06.003_b0270","doi-asserted-by":"crossref","first-page":"2128","DOI":"10.1016\/S0140-6736(16)31322-8","article-title":"Benralizumab, an anti-interleukin-5 receptor \u03b1 monoclonal antibody, as add-on treatment for patients with severe, uncontrolled, eosinophilic asthma (CALIMA): a randomised, double-blind, placebo-controlled phase 3 trial","volume":"388","author":"FitzGerald","year":"2016","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.prrv.2025.06.003_b0275","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/S2213-2600(17)30344-2","article-title":"Predictors of enhanced response with benralizumab for patients with severe asthma: pooled analysis of the SIROCCO and CALIMA studies","volume":"6","author":"FitzGerald","year":"2018","journal-title":"Lancet Respir Med"},{"issue":"1","key":"10.1016\/j.prrv.2025.06.003_b0280","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/S2213-2600(18)30406-5","article-title":"Long-term safety and efficacy of benralizumab in patients with severe, uncontrolled asthma: 1-year results from the BORA phase 3 extension trial","volume":"7","author":"Busse","year":"2019","journal-title":"Lancet Respir Med"},{"issue":"25","key":"10.1016\/j.prrv.2025.06.003_b0285","doi-asserted-by":"crossref","first-page":"2448","DOI":"10.1056\/NEJMoa1703501","article-title":"Oral glucocorticoid\u2013sparing effect of benralizumab in severe asthma","volume":"376","author":"Nair","year":"2017","journal-title":"N Engl J Med"},{"issue":"10423","key":"10.1016\/j.prrv.2025.06.003_b0290","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/S0140-6736(23)02284-5","article-title":"Reduction of daily maintenance inhaled corticosteroids in patients with severe eosinophilic asthma treated with benralizumab (SHAMAL): a randomised, multicentre, open-label, phase 4 study","volume":"403","author":"Jackson","year":"2024","journal-title":"Lancet"},{"issue":"11","key":"10.1016\/j.prrv.2025.06.003_b0300","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.1164\/rccm.202001-0093LE","article-title":"The use of benralizumab in the treatment of near-fatal asthma: a new approach","volume":"201","author":"Ramakrishnan","year":"2020","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.prrv.2025.06.003_b0305","unstructured":"Guidance N. Dupilumab for treating severe asthma with type 2 inflammation 2021; Available from: https:\/\/www.nice.org.uk\/guidance\/ta751."},{"key":"10.1016\/j.prrv.2025.06.003_b0310","unstructured":"Dupilumab F. Dupilumab in children for asthma. [cited 2024; Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2022\/761055s042lbl.pdf."},{"issue":"24","key":"10.1016\/j.prrv.2025.06.003_b0315","doi-asserted-by":"crossref","first-page":"2230","DOI":"10.1056\/NEJMoa2106567","article-title":"Dupilumab in children with uncontrolled moderate-to-severe asthma","volume":"385","author":"Bacharier","year":"2021","journal-title":"N Engl J Med"},{"issue":"8","key":"10.1016\/j.prrv.2025.06.003_b0320","doi-asserted-by":"crossref","first-page":"2621","DOI":"10.1111\/all.14872","article-title":"Dupilumab efficacy in adolescents with uncontrolled, moderate-to-severe asthma: LIBERTY ASTHMA QUEST","volume":"76","author":"Maspero","year":"2021","journal-title":"Allergy"},{"issue":"1","key":"10.1016\/j.prrv.2025.06.003_b0325","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1111\/all.14611","article-title":"Dupilumab is effective in type 2-high asthma patients receiving high-dose inhaled corticosteroids at baseline","volume":"76","author":"Bourdin","year":"2021","journal-title":"Allergy"},{"issue":"26","key":"10.1016\/j.prrv.2025.06.003_b0330","doi-asserted-by":"crossref","first-page":"2475","DOI":"10.1056\/NEJMoa1804093","article-title":"Efficacy and safety of dupilumab in glucocorticoid-dependent severe asthma","volume":"378","author":"Rabe","year":"2018","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.prrv.2025.06.003_b0335","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/S2213-2600(21)00322-2","article-title":"Long-term safety and efficacy of dupilumab in patients with moderate-to-severe asthma (TRAVERSE): an open-label extension study","volume":"10","author":"Wechsler","year":"2022","journal-title":"Lancet Respir Med"},{"issue":"26","key":"10.1016\/j.prrv.2025.06.003_b0340","doi-asserted-by":"crossref","first-page":"2486","DOI":"10.1056\/NEJMoa1804092","article-title":"Dupilumab efficacy and safety in moderate-to-severe uncontrolled asthma","volume":"378","author":"Castro","year":"2018","journal-title":"N Engl J Med"},{"issue":"suppl 66","key":"10.1016\/j.prrv.2025.06.003_b0345","first-page":"4570","article-title":"Assessment of the long-term safety and efficacy of dupilumab in children with asthma: LIBERTY ASTHMA EXCURSION","volume":"60","author":"Bacharier","year":"2022","journal-title":"Eur Respir J"},{"key":"10.1016\/j.prrv.2025.06.003_b0350","unstructured":"NICE. Tezepelumab for treating severe asthma. 2023; Available from: https:\/\/www.nice.org.uk\/guidance\/ta880\/chapter\/1-Recommendations."},{"key":"10.1016\/j.prrv.2025.06.003_b0355","unstructured":"FDA. Tezepelumab for severe asthma. 2021 [cited 2024; Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2021\/761224s000lbl.pdf."},{"issue":"2","key":"10.1016\/j.prrv.2025.06.003_b0360","doi-asserted-by":"crossref","DOI":"10.3390\/biomedicines11020437","article-title":"TSLP and HMGB1: inflammatory targets and potential biomarkers for precision medicine in asthma and COPD","volume":"11","author":"Furci","year":"2023","journal-title":"Biomedicines"},{"issue":"1","key":"10.1016\/j.prrv.2025.06.003_b0365","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1111\/j.1365-2222.2008.03151.x","article-title":"Human TSLP and TLR3 ligands promote differentiation of Th17 cells with a central memory phenotype under Th2-polarizing conditions","volume":"39","author":"Tanaka","year":"2009","journal-title":"Clin Exp Allergy"},{"issue":"4","key":"10.1016\/j.prrv.2025.06.003_b0370","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1016\/j.jaci.2019.06.011","article-title":"Thymic stromal lymphopoietin epigenetically upregulates Fc receptor \u03b3 subunit-related receptors on antigen-presenting cells and induces T(H)2\/T(H)17 polarization through dectin-2","volume":"144","author":"Liang","year":"2019","journal-title":"J Allergy Clin Immunol"},{"issue":"1","key":"10.1016\/j.prrv.2025.06.003_b0375","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1186\/s12931-020-01526-6","article-title":"NAVIGATOR: a phase 3 multicentre, randomized, double-blind, placebo-controlled, parallel-group trial to evaluate the efficacy and safety of tezepelumab in adults and adolescents with severe, uncontrolled asthma","volume":"21","author":"Menzies-Gow","year":"2020","journal-title":"Respir Res"},{"issue":"1","key":"10.1016\/j.prrv.2025.06.003_b0380","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1164\/rccm.202210-2005OC","article-title":"Efficacy of tezepelumab in severe, uncontrolled asthma: pooled analysis of the PATHWAY and NAVIGATOR clinical trials","volume":"208","author":"Corren","year":"2023","journal-title":"Am J Respir Crit Care Med"},{"issue":"1","key":"10.1016\/j.prrv.2025.06.003_b0385","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1186\/s12931-020-01541-7","article-title":"DESTINATION: a phase 3, multicentre, randomized, double-blind, placebo-controlled, parallel-group trial to evaluate the long-term safety and tolerability of tezepelumab in adults and adolescents with severe, uncontrolled asthma","volume":"21","author":"Menzies-Gow","year":"2020","journal-title":"Respir Res"},{"issue":"11","key":"10.1016\/j.prrv.2025.06.003_b0390","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1016\/S2213-2600(21)00226-5","article-title":"Effect of tezepelumab on airway inflammatory cells, remodelling, and hyperresponsiveness in patients with moderate-to-severe uncontrolled asthma (CASCADE): a double-blind, randomised, placebo-controlled, phase 2 trial","volume":"9","author":"Diver","year":"2021","journal-title":"Lancet Respir Med"},{"issue":"7","key":"10.1016\/j.prrv.2025.06.003_b0395","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1080\/02770903.2019.1604745","article-title":"Usability of mepolizumab single-use prefilled syringe for patient self-administration","volume":"57","author":"Bel","year":"2020","journal-title":"J Asthma"},{"key":"10.1016\/j.prrv.2025.06.003_b0400","doi-asserted-by":"crossref","first-page":"381","DOI":"10.2147\/JAA.S305114","article-title":"Functionality and performance of an accessorized pre-filled syringe and an autoinjector for at-home administration of tezepelumab in patients with severe, uncontrolled asthma","volume":"14","author":"Alpizar","year":"2021","journal-title":"J Asthma Allergy"},{"key":"10.1016\/j.prrv.2025.06.003_b0410","unstructured":"Clinicaltrials.gov. Tezepelumab. Available from: https:\/\/clinicaltrials.gov\/search?cond=Asthma&intr=TEZEPELUMAB."},{"issue":"2","key":"10.1016\/j.prrv.2025.06.003_b0415","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1183\/09031936.00202013","article-title":"International ERS\/ATS guidelines on definition, evaluation and treatment of severe asthma","volume":"43","author":"Chung","year":"2014","journal-title":"Eur Respir J"},{"issue":"2","key":"10.1016\/j.prrv.2025.06.003_b0425","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1056\/NEJMra2032506","article-title":"Biologic therapies for severe asthma","volume":"386","author":"Brusselle","year":"2022","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.prrv.2025.06.003_b0430","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1016\/j.jaip.2019.08.024","article-title":"Trends and disparities in asthma biologic use in the United States","volume":"8","author":"Inselman","year":"2020","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.prrv.2025.06.003_b0435","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2020.603312","article-title":"Molecular targets for biological therapies of severe asthma","volume":"11","author":"Pelaia","year":"2020","journal-title":"Front Immunol"},{"issue":"3","key":"10.1016\/j.prrv.2025.06.003_b0440","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1080\/02770903.2022.2082309","article-title":"One-year safety and tolerability of tezepelumab in Japanese patients with severe uncontrolled asthma: results of the NOZOMI study","volume":"60","author":"Shinkai","year":"2023","journal-title":"J Asthma"}],"container-title":["Paediatric Respiratory Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1526054225000636?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1526054225000636?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T20:51:19Z","timestamp":1777927879000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1526054225000636"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":85,"alternative-id":["S1526054225000636"],"URL":"https:\/\/doi.org\/10.1016\/j.prrv.2025.06.003","relation":{},"ISSN":["1526-0542"],"issn-type":[{"value":"1526-0542","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Choosing biologic therapy in children with severe asthma","name":"articletitle","label":"Article Title"},{"value":"Paediatric Respiratory Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.prrv.2025.06.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}